MedTrace Logo

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2016-01-21

Study results available
· View outcomes & findings →

Summary

To determine whether adding nebulized inhaled steroids to the standard care of acutely ill ED patients with refractory acute asthma helps improve forced expiratory volume at one second (FEV1) and decrease the need for hospitalization.

Conditions

Interventions

DRUG

Budesonide

2mg/dose by nebulizer, four doses over 3 hours

DRUG

albuterol

2.5mg/dose by nebulizer, 7 doses over 6 hours

DRUG

Ipratropium bromide

2.5 mg, one dose

DRUG

Prednisone

60mg PO

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Jacobi Medical Center

    collaborator OTHER

  • Nassau University Medical Center

    collaborator OTHER

  • Northwell Health

    lead OTHER

Principal Investigators

  • Robert Silverman, MD · Northwell Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00588406 on ClinicalTrials.gov